Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Breast Cancer
Interventions: DRUG: Capecitabine
Sponsor: Stanford University